(PBH) Prestige Brand Holdings - Overview
Stock: Analgesic Powders, Diaper Rash, Throat Relief, Eye Care, Wart Removal
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 24.2% |
| Relative Tail Risk | -2.49% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.51 |
| Alpha | -22.48 |
| Character TTM | |
|---|---|
| Beta | 0.493 |
| Beta Downside | 0.404 |
| Drawdowns 3y | |
|---|---|
| Max DD | 35.49% |
| CAGR/Max DD | 0.09 |
Description: PBH Prestige Brand Holdings January 12, 2026
Prestige Consumer Healthcare Inc. (NYSE: PBH) manufactures and markets a broad portfolio of over-the-counter (OTC) health and personal-care brands-including BC & Goody’s analgesic powders, Chloraseptic sore-throat sprays, Clear Eyes eye-relief drops, Compound W wart removers, and DenTek dental accessories-across North America, Australia, and other international markets. The business is split into two reporting segments: North American OTC Healthcare and International OTC Healthcare, selling primarily through mass merchandisers, drug and convenience stores, and growing e-commerce channels.
Key operating metrics show PBH generated roughly $1.5 billion in revenue for FY 2023, with an adjusted EBITDA margin near 10 %, reflecting the relatively high-margin nature of branded OTC products. The U.S. OTC market, valued at about $35 billion, is projected to grow 3-4 % annually, driven by the “self-care” trend and an aging consumer base that favors convenient, non-prescription solutions. Inflationary pressures on discretionary spending have modestly shifted demand toward lower-priced private-label alternatives, prompting PBH to emphasize price-elastic, high-visibility SKUs and expand its direct-to-consumer digital footprint.
For a deeper quantitative dive, you might explore PBH’s metrics on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 200.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA -0.26 > 1.0 |
| NWC/Revenue: 32.66% < 20% (prev 24.66%; Δ 8.01% < -1%) |
| CFO/TA 0.08 > 3% & CFO 263.4m > Net Income 200.8m |
| Net Debt (921.9m) to EBITDA (356.9m): 2.58 < 3 |
| Current Ratio: 3.70 > 1.5 & < 3 |
| Outstanding Shares: last quarter (49.3m) vs 12m ago -1.47% < -2% |
| Gross Margin: 56.36% > 18% (prev 0.55%; Δ 5581 % > 0.5%) |
| Asset Turnover: 32.87% > 50% (prev 33.48%; Δ -0.61% > 0%) |
| Interest Coverage Ratio: 7.71 > 6 (EBITDA TTM 356.9m / Interest Expense TTM 42.5m) |
Altman Z'' 3.95
| A: 0.11 (Total Current Assets 497.4m - Total Current Liabilities 134.6m) / Total Assets 3.44b |
| B: 0.48 (Retained Earnings 1.65b / Total Assets 3.44b) |
| C: 0.10 (EBIT TTM 327.5m / Avg Total Assets 3.38b) |
| D: 1.00 (Book Value of Equity 1.61b / Total Liabilities 1.62b) |
| Altman-Z'' Score: 3.95 = AA |
Beneish M -2.91
| DSRI: 1.22 (Receivables 199.0m/163.5m, Revenue 1.11b/1.11b) |
| GMI: 0.98 (GM 56.36% / 55.22%) |
| AQI: 0.95 (AQ_t 0.82 / AQ_t-1 0.86) |
| SGI: 1.00 (Revenue 1.11b / 1.11b) |
| TATA: -0.02 (NI 200.8m - CFO 263.4m) / TA 3.44b) |
| Beneish M-Score: -2.91 (Cap -4..+1) = A |
What is the price of PBH shares?
Over the past week, the price has changed by +2.58%, over one month by +4.93%, over three months by +9.56% and over the past year by -13.86%.
Is PBH a buy, sell or hold?
- StrongBuy: 3
- Buy: 0
- Hold: 3
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the PBH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 77.3 | 18% |
| Analysts Target Price | 77.3 | 18% |
| ValueRay Target Price | 65.3 | -0.4% |
PBH Fundamental Data Overview February 03, 2026
P/E Forward = 13.459
P/S = 2.9002
P/B = 1.6986
P/EG = 2.1709
Revenue TTM = 1.11b USD
EBIT TTM = 327.5m USD
EBITDA TTM = 356.9m USD
Long Term Debt = 993.1m USD (from longTermDebt, last quarter)
Short Term Debt = 8.62m USD (from shortTermDebt, last quarter)
Debt = 1.04b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 921.9m USD (from netDebt column, last quarter)
Enterprise Value = 4.14b USD (3.22b + Debt 1.04b - CCE 119.1m)
Interest Coverage Ratio = 7.71 (Ebit TTM 327.5m / Interest Expense TTM 42.5m)
EV/FCF = 16.22x (Enterprise Value 4.14b / FCF TTM 255.5m)
FCF Yield = 6.17% (FCF TTM 255.5m / Enterprise Value 4.14b)
FCF Margin = 23.00% (FCF TTM 255.5m / Revenue TTM 1.11b)
Net Margin = 18.08% (Net Income TTM 200.8m / Revenue TTM 1.11b)
Gross Margin = 56.36% ((Revenue TTM 1.11b - Cost of Revenue TTM 484.7m) / Revenue TTM)
Gross Margin QoQ = 56.21% (prev 54.16%)
Tobins Q-Ratio = 1.20 (Enterprise Value 4.14b / Total Assets 3.44b)
Interest Expense / Debt = 0.96% (Interest Expense 10.0m / Debt 1.04b)
Taxrate = 38.94% (26.9m / 69.1m)
NOPAT = 199.9m (EBIT 327.5m * (1 - 38.94%))
Current Ratio = 3.70 (Total Current Assets 497.4m / Total Current Liabilities 134.6m)
Debt / Equity = 0.57 (Debt 1.04b / totalStockholderEquity, last quarter 1.82b)
Debt / EBITDA = 2.58 (Net Debt 921.9m / EBITDA 356.9m)
Debt / FCF = 3.61 (Net Debt 921.9m / FCF TTM 255.5m)
Total Stockholder Equity = 1.83b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.94% (Net Income 200.8m / Total Assets 3.44b)
RoE = 11.00% (Net Income TTM 200.8m / Total Stockholder Equity 1.83b)
RoCE = 11.62% (EBIT 327.5m / Capital Employed (Equity 1.83b + L.T.Debt 993.1m))
RoIC = 7.09% (NOPAT 199.9m / Invested Capital 2.82b)
WACC = 5.99% (E(3.22b)/V(4.26b) * Re(7.73%) + D(1.04b)/V(4.26b) * Rd(0.96%) * (1-Tc(0.39)))
Discount Rate = 7.73% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -0.86%
[DCF Debug] Terminal Value 86.22% ; FCFF base≈255.1m ; Y1≈261.2m ; Y5≈289.9m
Fair Price DCF = 155.2 (EV 8.38b - Net Debt 921.9m = Equity 7.46b / Shares 48.1m; r=5.99% [WACC]; 5y FCF grow 2.28% → 2.90% )
EPS Correlation: 8.16 | EPS CAGR: -4.41% | SUE: -4.0 | # QB: 0
Revenue Correlation: -5.09 | Revenue CAGR: -0.03% | SUE: 2.42 | # QB: 1
EPS next Year (2027-03-31): EPS=4.83 | Chg30d=-0.009 | Revisions Net=-1 | Growth EPS=+5.9% | Growth Revenue=+2.3%